ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
ETF Series Solutions Trust Range Cancer Therapeutics

ETF Series Solutions Trust Range Cancer Therapeutics (CNCR)

15.97
0.62
(4.04%)
Closed July 17 4:00PM
15.99
0.02
(0.13%)
After Hours: 7:59PM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
15.97
Bid
11.94
Ask
19.88
Volume
6,328
15.44 Day's Range 15.99
9.22 52 Week Range 18.00
Market Cap
Previous Close
15.35
Open
15.44
Last Trade
66
@
15.97
Last Trade Time
Financial Volume
$ 100,536
VWAP
15.8875
Average Volume (3m)
9,839
Shares Outstanding
800,000
Dividend Yield
-
PE Ratio
-2.77
Earnings Per Share (EPS)
-5.77
Revenue
70k
Net Profit
-4.62M

About ETF Series Solutions Trust Range Cancer Therapeutics

The investment seeks to track the total return performance, before fees and expenses, of the Loncar Cancer Immunotherapy Index. The index is composed of the common stock of approximately 25 pharmaceutical or biotechnology companies identified by the funds index provider, as having a high strategic f... The investment seeks to track the total return performance, before fees and expenses, of the Loncar Cancer Immunotherapy Index. The index is composed of the common stock of approximately 25 pharmaceutical or biotechnology companies identified by the funds index provider, as having a high strategic focus on the development of drugs that harness the bodys own immune system to fight cancer. The adviser attempts to invest all, or substantially all, of its assets in the component securities and ADRs that make up the index. Normally it will invest at least 80% of its total assets in the component securities of the index. The fund is non-diversified. Show more

Sector
Mgmt Invt Offices, Open-end
Industry
Mgmt Invt Offices, Open-end
Headquarters
Milwaukee, Wisconsin, USA
Founded
1970
ETF Series Solutions Trust Range Cancer Therapeutics is listed in the Mgmt Invt Offices, Open-end sector of the NASDAQ with ticker CNCR. The last closing price for ETF Series Solutions Tru... was $15.35. Over the last year, ETF Series Solutions Tru... shares have traded in a share price range of $ 9.22 to $ 18.00.

ETF Series Solutions Tru... currently has 800,000 shares outstanding. The market capitalization of ETF Series Solutions Tru... is $12.28 million. ETF Series Solutions Tru... has a price to earnings ratio (PE ratio) of -2.77.

CNCR Latest News

EXCHANGE TRADED CONCEPTS, LLC., ANNOUNCES COMPLETION OF FUND REORGANIZATION

EXCHANGE TRADED CONCEPTS, LLC., ANNOUNCES COMPLETION OF FUND REORGANIZATION PR Newswire OKLAHOMA CITY, Oct. 23, 2023 OKLAHOMA CITY, Oct. 23, 2023 /PRNewswire/ -- Exchange Traded Concepts, LLC...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
12.3317.08211143713.6415.9913.58702814.79808156SP
42.1515.557163531113.8215.9913.00131584613.66200442SP
121.6911.834733893614.2815.9913.0013983914.36704302SP
261.9513.908701854514.021813.00132396415.85774509SP
523.2125.156739811912.76189.221387015.32688488SP
156-13.59-45.974289580529.5631.79.22920816.46283871SP
260-5.25-24.740810556121.2235.8189.22995620.48257371SP

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
SILOSilo Pharma Inc
$ 2.38
(122.43%)
176.27M
TKLFYoshitsu Company Ltd
$ 0.6117
(99.74%)
318.35M
NAASNaaS Technology Inc
$ 4.6301
(65.36%)
22.46M
ATGLAlpha Technology Group Limited
$ 4.18
(47.18%)
920.43k
LCFYLocafy Ltd
$ 5.34
(46.30%)
6.5M
JEWLAdamas One Corporation
$ 0.33
(-25.88%)
275.38k
AEHLAntelope Enterprise Holdings Ltd
$ 4.04
(-21.86%)
488.93k
AMIXAutonomix Medical Inc
$ 1.09
(-21.01%)
6.99M
ASLNASLAN Pharmaceuticals Ltd
$ 1.10
(-20.29%)
599.54k
CYNCYNGN Inc
$ 7.3799
(-19.61%)
1.16M
TKLFYoshitsu Company Ltd
$ 0.6117
(99.74%)
318.35M
MAXNMaxeon Solar Technologies Ltd
$ 0.2524
(11.19%)
246.61M
NVDANVIDIA Corporation
$ 126.36
(-1.62%)
214.79M
SILOSilo Pharma Inc
$ 2.38
(122.43%)
176.27M
SQQQProShares UltraPro Short QQQ
$ 7.46
(0.00%)
130.15M

CNCR Discussion

View Posts
ShadowVolcano37 ShadowVolcano37 2 months ago
Yeah I hear you regarding the new immunotherapy options. I think it's becoming real, although still very expensive.
👍️0
ShadowVolcano37 ShadowVolcano37 2 months ago
Research offers exciting prospects for improving immunotherapy's effectiveness against cancer
https://www.msn.com/en-us/news/other/immunotherapy-a-beacon-of-hope-in-cancer-treatment/
👍️0
ShadowVolcano37 ShadowVolcano37 3 months ago
Cancer Immunotherapy is such an interesting field. I hope it will continue to grow!
👍️0
PennyStock Alert PennyStock Alert 5 years ago
https://twitter.com/bradloncar
👍️0
chmcnfunds chmcnfunds 6 years ago
In @ $24.05. Maybe too early, but near 9 month low:



CNCR
👍️0
chmcnfunds chmcnfunds 6 years ago
Latest Loncar positions and weighs:

http://www.loncarindex.com/cancer-immunotherapy-index-weights


CNCR
👍️0
chmcnfunds chmcnfunds 7 years ago
Loncar blog has increasingly useful data sets:

http://www.loncarblog.com/
👍️0
chmcnfunds chmcnfunds 8 years ago
Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance

Two New Immunotherapy Companies Added to the Index

Loncar Investments, LLC today announced the result of the semi-annual rebalance and reconstitution of the Loncar Cancer Immunotherapy Index, a group of the top 30 companies developing cancer immunotherapy treatments and discovering new ways to use the body’s immune system to fight cancer.

The index committee has added BeiGene (Nasdaq: BGNE) and Compugen (Nasdaq: CGEN) to the index.

These additions replace Celyad (Nasdaq: CYAD) and Immune Design (Nasdaq: IMDZ).

“Transformative drug development is happening all over the world,” said Brad Loncar, Chairman of the index committee. “We are pleased to welcome our first components to the index from China and Israel and look forward to following their contributions to the field of cancer immunotherapy.”

The index committee has further decided to institute a minimum equity liquidity threshold of 50,000 shares or $500,000 in average daily trading volume for any index component going forward.

Effective this week, all index holdings have been rebalanced to hold equal weight. The index is rebalanced and reconstituted semi-annually. The next rebalance will occur on December 20, 2016.

Loncar Investments is a proud partner of the Cancer Research Institute, the world’s only nonprofit organization dedicated exclusively to harnessing the immune system’s power to conquer all cancers. To learn about how to give to CRI, please visit here.

Why immunotherapy: Cancer immunotherapy has become an important sector in the biotechnology space and is changing the way many cancers are treated. While traditional medicines like chemotherapies often give cancer a broad punch, the benefit of using immunotherapy is derived from the immune system's dynamic nature and the way it can more precisely be tailored to fight a patient's disease. Some immunotherapies have already exhibited uncommon results in clinical trials including partial and complete responses in late stage cancer patients.

About the index: The Loncar Cancer Immunotherapy Index is an equal-weighted index of 30 top immunotherapy companies rebalanced and reconstituted on a semi-annual basis. Price and return data are independently calculated on a daily basis by Indxx, LLC. This is a sector index similar to Technology sector indices (Internet, Cyber Security, Cloud Computing, etc.). Sector indices allow investors to track interest areas more precisely than broad indices. Additional info can be found at the index’s dedicated website, www.LoncarIndex.com.

Index provider: Loncar Investments LLC was founded by independent biotech investor and analyst Brad Loncar. Mr. Loncar regularly provides his distinctive insight and analysis on this market segment to the investment community via a variety of publishing platforms. Through Loncar Investments LLC, Mr. Loncar has incorporated his extensive research into biotech companies and technologies into developing an index focused on precise investment opportunities. He previously worked in the financial services industry at Franklin Templeton Investments, and was appointed to serve in a Senior Adviser role at the U.S. Department of the Treasury. Mr. Loncar can be followed on Twitter at @bradloncar.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160622005067/en/

Leah Katsanis for ISE ETF Ventures
610-228-2117
ise@gregoryfca.com
👍️0
chmcnfunds chmcnfunds 8 years ago
Brad Loncar tweets:

https://twitter.com/bradloncar

CNCR
👍️0
chmcnfunds chmcnfunds 8 years ago
Current Loncar holdings:

http://www.loncarfunds.com/holdings.aspx

CNCR
👍️0

Your Recent History

Delayed Upgrade Clock